Compositions for disrupting biofilm formation and for treating biofilm-related disorders
The disclosure relates to thiosulfur containing compositions, in particular propyl-propane thiosulfonate (PTSO) and propyl-propane-thiosulfinate (PTS). Such compositions are useful for treating infection and reducing or degrading biofilms both in vivo and in vitro. In particular, such compositions are useful in the treatment of biofilm-related disorders, including but not limited to mastitis, digital dermatitis, and chronic wound infections.
1 . A method for treating a biofilm-related infection in an individual, said method comprising administering to an individual in need thereof a composition comprising a compound according to formula I
wherein R1 and R2 are independently selected from optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl.
2 . The method of claim 1 , wherein the compound is propyl-propane thiosulfonate (PTSO).
3 . The method of claim 1 , wherein said method further comprises administering to an individual in need thereof a compound for use according to formula II
wherein R3 and R4 are independently selected from optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, provided that Formula II is not
4 . The method of claim 3 , wherein the compound according to formula II is propyl-propane-thiosulfinate (PTS).
5 . The method of claim 1 , wherein said method further comprises administering to an individual in need thereof a compound having Formula III
wherein n is 1, 2, or 3 and R1 and R2 are independently selected from optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl,
provided that Formula III is not
6 . The method of claim 1 , wherein said method further comprises administering to an individual in need thereof an antimicrobial agent and/or an anti-inflammatory agent.
7 . The method of claim 1 , wherein the biofilm-related infection is a chronic and/or persistent infection.
8 . The method of claim 1 , wherein the biofilm-related infection is digital dermatitis or a chronic wound infection.
9 . The method of claim 1 , wherein the biofilm-related infection is an infection of the mammary gland.
10 . The method of claim 9 , wherein the biofilm-related infection is mastitis.
11 . The method of claim 1 , wherein the individual is a mammal.
12 . The method of claim 1 , wherein the individual is a ruminant.
13 . The method of claim 1 , wherein the composition is substantially free of diallyl thiosulfinate.
14 . The method of claim 1 , wherein the biofilm comprises bacteria, yeast, fungi, microalgae, or a combination thereof.